Engflag

Nexpro-IT

Quick links to important sections

Nexpro-IT

Nexpro-IT_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nexpro-IT

Property Description
Active Ingredient Esomeprazole, Itopride
Form Oral Capsule (Fixed-Dose Combination)
Pharmacological Class Proton Pump Inhibitor, Prokinetic Agent
General Purpose Simultaneous management of acid secretion and gastric motility
Origin Synthetic Compounds

Nexpro-IT: A Fixed-Dose Combination Gastrointestinal Agent

Nexpro-IT is a branded oral capsule classified as a fixed-dose combination (FDC) medicinal product used for managing issues within the upper digestive tract. This combination drug is defined by its strategic pairing of two distinct, synthetic compounds in a single preparation, distinguishing it from treatments containing only one active ingredient. The product is categorized as a gastrointestinal medication and an anti-reflux agent, reflecting its dual mode of action aimed at both the chemical environment and the mechanical function of the stomach.

What are the Active Ingredients and Pharmacological Class?

The two active ingredients in the capsule are Esomeprazole and Itopride, each belonging to a different, critical pharmacological class. Esomeprazole is an established Proton Pump Inhibitor (PPI), a class known for its ability to manage gastric acid secretion by inhibiting the H^+/K^+ ATPase enzyme. The second component, Itopride, is categorized as a Prokinetic agent, which works to enhance muscle movement in the digestive system. The pairing of PPIs with prokinetic agents is intended to address both reflux and motility disorders.

General Therapeutic Purpose: Addressing Acid and Motility

The general purpose of Nexpro-IT is to achieve a synergistic action by simultaneously tackling the problems of excessive acidity and slow stomach movement, a scenario commonly associated with complex digestive discomfort. The Esomeprazole component works to suppress the production of acid, reducing the corrosive content within the stomach. Concurrently, the Itopride component helps to accelerate gastric emptying and normalize gastrointestinal motility, ensuring contents move efficiently through the digestive system. This combined approach is used for addressing discomfort that arises from both chemical irritation and mechanical dysfunction in the stomach, providing a more robust intervention than targeting either factor alone.

Regulatory References

  1. Proton Pump Inhibitor (PPI)
  2. Prokinetic agent
  3. gastric acid secretion
  4. gastrointestinal motility
  5. gastric emptying
  6. Clinical Review on PPIs and Prokinetics

What side effects are possible with Nexpro-IT?

Official Safety Profile Overview

The safety profile for this fixed-dose combination of Esomeprazole and Itopride is based on the documented adverse events and risk classifications from official regulatory sources. Adverse reactions are grouped by their documented frequency in clinical use, ranging from Common to Very Rare, and classified according to the specific physiological system affected.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common Headache, Abdominal pain, Diarrhea, Flatulence, Nausea, Vomiting, Constipation
Uncommon Dizziness, Insomnia, Dry mouth, Skin rash, Urticaria

These effects fall under System-Organ Classes including Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Safety Notes

The regulatory labeling includes documentation of rare but clinically significant adverse reactions. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome, and serious effects on the blood system like Agranulocytosis, or Hepatic failure, typically classified as Very Rare. Certain metabolic risks, notably Hypomagnesemia and bone fracture, are officially associated with long-term use (one year or more) of the Proton Pump Inhibitor component.

Specific restrictions define that the product is contraindicated in cases of known hypersensitivity to the components and in pre-existing conditions where increased gastrointestinal motility could be harmful, such as mechanical obstruction or perforation. Caution is also noted regarding use in individuals with severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official information regarding an overdose of this fixed-dose combination, Esomeprazole and Itopride, is based on the documented effects of its individual components. It is mandated by regulatory authorities that immediate medical attention must be sought following any suspected over-ingestion of this medication to initiate appropriate care.

Documented Manifestations

Reported overdose scenarios involving the Esomeprazole component, including doses up to 2,400 mg, have documented specific clinical signs. These signs affect the central nervous and cardiovascular systems, and include confusion, drowsiness, nausea, vomiting, and rapid heartbeat (tachycardia). These manifestations define the official scope of a potential overdose presentation.

Management and Official Constraints

Treatment for an overdose is strictly symptomatic and supportive. Regulatory bodies state that no specific antidote is known for the active ingredients in this combination. The clinical approach is therefore directed at managing the documented signs and symptoms. Officially described supportive measures applicable for the components include general symptomatic therapy and the use of gastric lavage for the Itopride component in cases of excessive overdosage. A constraint noted in the regulatory context is that dialysis is not expected to be effective in removing the Esomeprazole component due to its extensive binding to plasma proteins.

Therapeutic Uses of Nexpro-IT

Quick Facts: Nexpro-IT Therapeutic Uses

Condition Treated
Gastroesophageal Reflux Disease (GERD)
Peptic Ulcer Disease (Stomach and Duodenal Ulcers)
Symptoms associated with acid reflux and heartburn

Main Therapeutic Uses and Benefits of Nexpro-IT

Nexpro-IT is prescribed to manage specific conditions within the digestive tract that are related to excessive stomach acid production and impaired gastric movement. The combination medication works to reduce the amount of acid the stomach produces while simultaneously improving the motility of the digestive system.

The primary indication for this medication is the treatment of Gastroesophageal Reflux Disease (GERD). This condition involves the persistent backward flow of stomach acid into the esophagus (food pipe), which can cause irritation, inflammation, and symptoms such as heartburn and acid regurgitation. By reducing acid levels and promoting the proper clearance of stomach contents, Nexpro-IT helps resolve these symptoms and assists in the healing of any associated esophageal irritation.

It is also used in the management of Peptic Ulcer Disease, which includes ulcers in the stomach lining and the upper part of the small intestine (duodenum). Lowering the acid concentration supports the body’s natural process for healing these ulcers. The medication plays a role in managing these severe acid-related disorders.

Regulatory References

  1. Torrent Pharmaceuticals prescribing information

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Nexpro-IT?

Eligibility to use Nexpro-IT, a fixed-dose combination of esomeprazole and itopride, is strictly defined by regulatory documents based on patient population and pre-existing conditions.

Absolute Contraindications (Must Not Use)

Individuals are formally contraindicated and must not use this medicine if they have a known hypersensitivity to esomeprazole, itopride, substituted benzimidazoles, or any component of the formulation. Use is also prohibited in patients taking the anti-HIV drug nelfinavir or those with gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Age and Physiological Restrictions

  • Adults (ge 18 years of age) are generally eligible for use.
  • Children and Adolescents (under 12 years of age): Use of the fixed-dose combination is not recommended as safety and effectiveness have not been established.
  • Pregnancy and Lactation: Use during pregnancy and lactation is generally not recommended due to limited data and the potential for drug excretion into breast milk.

Condition-Specific Limitations

Patients with severe hepatic impairment (liver disease) must have the dose of the esomeprazole component restricted. Use in patients with severe renal insufficiency requires caution due to limited clinical experience. The medicine is also restricted or prohibited for patients with certain heart rhythm problems, epilepsy, or specific prolactin-dependent tumors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nexpro-IT contains two active components, esomeprazole and itopride, and its interaction profile is determined by both. Esomeprazole can significantly alter the absorption and metabolism of other medicines, primarily through two mechanisms.

First, esomeprazole reduces stomach acid, which can affect drugs whose absorption is dependent on gastric pH. This results in decreased absorption and reduced efficacy of antifungals like ketoconazole and itraconazole, and the cancer medicine erlotinib. Conversely, the absorption of digoxin may be increased.

Second, esomeprazole inhibits the liver enzyme CYP2C19. This inhibition can lead to increased plasma concentrations of other medicines metabolized by this enzyme, such as the anticoagulant warfarin, the antiepileptic phenytoin, and the anxiolytic diazepam. Close monitoring is required when combining esomeprazole with these medicines.

Specific restrictions include a contraindication for co-administration with the HIV medicine nelfinavir, and atazanavir is not recommended. When used with methotrexate or the immunosuppressant tacrolimus, careful monitoring and dose adjustment may be necessary.

Itopride, the prokinetic component, increases gastrointestinal motility, which may influence the absorption rate of co-administered oral medicines, particularly those with a narrow therapeutic index or specialized release forms. The effect of itopride may be lessened by anticholinergic medicines.

Mechanism of Action

Irreversible H^+/ K^+- ATPase Blockade

The action of Esomeprazole begins as an acid-activated prodrug that accumulates in the secretory canaliculi of the gastric parietal cells. Here, it forms an irreversible covalent bond with the H^+/ K^+- ATPase enzyme (the proton pump), the final step in acid secretion. This mechanism permanently inhibits the enzyme's function, leading to a long-duration elevation of the intragastric pH by reducing both basal and stimulated acid output.

Dual Modulation of Peripheral Cholinergic Signaling

Itopride provides a complementary mechanism within the enteric nervous system by acting as an antagonist at peripheral Dopamine D2 receptors and as an inhibitor of the enzyme Acetylcholinesterase ( AChE). This dual action boosts the effective concentration of the pro-motility neurotransmitter Acetylcholine ( ACh), resulting in enhanced smooth muscle contractions, accelerated gastric emptying, and increased Lower Esophageal Sphincter (LES) tone.

Mechanistic Synergy

The mechanisms are coordinated to simultaneously achieve reduction of HCl concentration and modulation of upper GI motility. This synergy results in a coordinated modulation of both the secretory and motor functions of the upper GI tract, supporting rapid transit of contents and sustained pH elevation.

Dosage and Administration Information

Administration of Nexpro-IT

Nexpro-IT is prescribed as an oral fixed-dose combination (FDC) capsule containing Esomeprazole 40 mg and Itopride 150 mg. The drug is characterized by specific methods and timing for proper administration.

Property Official Instruction
Route of Administration Oral route only.
Standard Adult Dose One capsule (Esomeprazole 40 mg / Itopride 150 mg) once daily.
Timing Must be taken on an empty stomach or at least one hour before a meal.
Preparation/Handling The capsule must be swallowed whole with water. Do not chew, crush, or open the capsule, as this compromises the sustained-release mechanism.
Missed Dose If a dose is missed, take it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed one and continue the regular schedule; do not take two doses to make up for a single missed dose.
Population Rules Not recommended for use in children under 12 years of age. A maximum dosage of 20 mg Esomeprazole is recommended for patients with severe hepatic impairment (Child-Pugh Class C), which may necessitate a change from this FDC strength.

The proper use protocol requires adherence to the once-daily, pre-meal timing. This is necessary for optimal drug delivery. The constraint against crushing or opening the capsule is maintained to preserve the integrity of the controlled-release delivery system for both components.

Recent Clinical Evidence

Research evidence / Overview of studies for Nexpro-IT

Evidence for Use in Gastroesophageal Reflux Disease (GERD)

This section will summarize the available clinical evaluation of the combination therapy for GERD, including the types of short-term randomized trials and systematic reviews that measured symptom change and tissue change.

Nexpro-IT, as a combination therapy, was studied for the management of GERD, a condition involving periods of heightened symptoms. The primary research for this combination is composed of short-term Randomized Controlled Trials (RCTs), where patients were randomly assigned to different treatment groups, and systematic reviews that combined the results of these trials. Researchers explored outcomes related to physical discomfort, such as heartburn and regurgitation, and also monitored tissue change in erosive esophagitis.

Studies reported measurements of changes observed during the study period in the patients who were studied. Specifically, studies described patterns observed in the trials regarding the measured rate of symptom change over the course of treatment. The evidence contributes to understanding symptom patterns in this patient group.

Comparing Combination Therapy to Standard Treatments

This part will detail the structure of studies that compared the combination product against single-agent therapy or placebo, describing what outcomes were measured in these comparative effectiveness trials.

Trials was evaluated in scenarios comparing the combination therapy to single-agent therapy (PPI monotherapy). These studies research examined whether the comparison groups differed on outcomes related to systemic or functional imbalance. Researchers sought to understand the patient-reported outcomes describing perceived discomfort when the combination was applied versus when the PPI was used alone.

The short-term findings describe group patterns observed in the studies and reported different symptom change patterns between the comparison groups. However, it is noted that findings were mixed across some larger scientific syntheses (meta-analyses), and research provides context but not individual predictions about comparative outcomes.

Long-Term Studies and Follow-up Duration

This segment will outline the duration of clinical follow-up provided by the main studies, specifically noting what is known and what remains uncharacterized regarding intermediate and long-term outcomes of the treatment regimen.

The majority of primary research was observed in short, defined time intervals, with most trials monitoring responses over time intervals of four to twelve weeks. These study results reflect the specific conditions under which they were conducted and primarily document acute or short-term changes.

There is limited information for long-term outcomes and the data are still emerging. The research landscape does not fully establish the long-term effects or the durability of symptom evolution for this specific combination regimen beyond the few months studied. Therefore, data related to outcomes reflecting daily functioning or activity level over extended periods remains an area where certainty remains low.

Frequently Asked Questions (FAQ)

Common questions about Nexpro-IT (FAQ)

Q: How long does it take for Nexpro-IT to start working to lower blood sugar?

Nexpro-IT begins to affect blood sugar levels within a few days of starting treatment. However, the full therapeutic benefit and maximum blood sugar reduction are typically observed after several weeks, which is a common timeframe cited in clinical information, as the body adjusts to the medication. Consistency with the prescribed regimen is generally important for therapeutic outcomes.

Q: Can I drink alcohol while taking Nexpro-IT?

The official product information strongly cautions against drinking excessive amounts of alcohol while taking Nexpro-IT. The combination may increase the risk of a serious health condition known as lactic acidosis, according to regulatory warnings. Even small amounts of alcohol may still present a risk, and guidance from a healthcare professional is crucial. It is essential to discuss alcohol consumption with a healthcare provider to understand the risks involved with your specific consumption habits.

Q: What are the most common side effects of Nexpro-IT, and how can I manage them?

The most common side effects are gastrointestinal, including diarrhea, nausea, and stomach upset. These side effects are often reported to be more noticeable when starting the medication. Label information often suggests taking the medication with food, as this approach may help improve gastrointestinal tolerability. These issues commonly lessen in severity after the first few weeks of consistent use.

Q: Is Nexpro-IT used for weight loss, even if a person does not have diabetes?

Nexpro-IT is only FDA-approved and prescribed to treat type 2 diabetes and to lower blood sugar. While not its approved use, in some clinical settings, it has been associated with weight reduction, particularly in individuals with insulin resistance. It is important to understand that Nexpro-IT is approved for type 2 diabetes, and its use for weight management should only occur under the direction of a healthcare professional who can assess the individual's overall health needs.

How should Nexpro-IT be stored and disposed of?

Storage and Disposal Requirements for Nexpro-IT

The storage and handling of Nexpro-IT (esomeprazole/itopride) must adhere strictly to regulatory standards to ensure product stability and safety.

Storage Conditions

  • Temperature: Store at Controlled Room Temperature, defined as 20^circC to 25^circC (68^circF to 77^circF). Storage must not exceed 30^circC, and the product must not be frozen.
  • Environmental Protection: Keep the container tightly closed and protect the capsules from light and excess moisture; storage in high-humidity areas, such as a bathroom, is prohibited.
  • Container and Safety: The medication must be kept in its original, light-resistant container and stored out of the reach and sight of children.

Disposal Instructions

Disposal of expired or unused Nexpro-IT should prioritize a drug take-back program. If a take-back option is unavailable, the capsules should be mixed with an undesirable substance, placed in a sealed bag, and discarded with household trash. The product and its contents must be prevented from entering drains or watercourses, as disposal must align with environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nexpro-IT found in:

A-Z Index: